BACKGROUND: Ocular redness (OR) is a common clinical presentation that can significantly impact patients' health-related quality of life (HRQoL), yet treatment options have historically been limited by side effects and efficacy concerns. Brimonidine tartrate 0.025% represents a newer therapeutic option, but real-world perspectives from healthcare professionals (HCPs) on its clinical utility remain understudied.

METHODS: A cross-sectional exploratory qualitative interview study was conducted with 18 ophthalmologists purposively recruited from a sponsor-acquired list. Participants had experience prescribing or recommending brimonidine tartrate 0.025% and were interviewed across Spain, Portugal, Poland, the United States, and Greece. Semi-structured interviews explored current treatment landscapes, unmet needs, and experiences with brimonidine tartrate 0.025%. Transcripts were analysed using qualitative content analysis.

RESULTS: Participants reported OR as highly prevalent in their practice, with dry eye disease being the most commonly cited underlying cause. HCPs described significant HRQoL impact on patients, including social embarrassment, workplace concerns, and emotional distress. Prior to brimonidine tartrate 0.025%, treatment options were limited, with traditional vasoconstrictors avoided due to rebound redness and tachyphylaxis. All participants reported brimonidine tartrate 0.025% as effective, with rapid onset and good tolerability. Key advantages included lack of rebound redness and suitability for various patient types.

CONCLUSION: This study with brimonidine tartrate 0.025% prescribers found it addresses a significant unmet need in OR management, providing effective relief with improved safety profile compared to traditional options. However, emphasis on proper diagnosis and use remains crucial. Keywords: ocular redness, conjunctival hyperaemia, brimonidine tartrate, healthcare professionals, qualitative research, treatment satisfaction